Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 4 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

efgartigimod alfa 2Rituximab 2Hizentra 2zilucoplan 1thymoglobulin 1rozanolixizumab 1rhoA GTP-Binding Protein 1prednylidene 1iscalimab 1inebilizumab 1gamma-Globulins 1eculizumab 1deltacortene 1carmustine, poliferprosan 20 drug combination 1apraclonidine 1Sternotomy 1Prednisone 1Peripheral Blood Stem Cell Transplantation 1Methotrexate 1Melphalan 1Immunoglobulins, Intravenous 1HBM9161 1Fluid Therapy 1Etoposide 1Cytarabine 1Carmustine 1CK-2017357 1Bortezomib 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myasthenia Gravis × rozanolixizumab × Clear all
NCT03052751 2021-08-03

Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis

UCB Pharma

Phase 2 Completed
43 enrolled 12 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡